Syncona Portfolio Ltd Acquires Shares of 16,640,720 Autolus Therapeutics PLC Sponsored ADR $AUTL

Syncona Portfolio Ltd purchased a new position in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 16,640,720 shares of the company’s stock, valued at approximately $26,625,152. Autolus Therapeutics makes up 0.1% of Syncona Portfolio Ltd’s investment portfolio, making the stock its biggest position. Syncona Portfolio Ltd owned approximately 6.25% of Autolus Therapeutics as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Armistice Capital LLC boosted its stake in shares of Autolus Therapeutics by 12.2% during the 4th quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock worth $34,825,000 after acquiring an additional 1,900,000 shares during the period. Bank of America Corp DE lifted its stake in shares of Autolus Therapeutics by 108.1% in the 3rd quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock valued at $3,308,000 after acquiring an additional 1,054,458 shares during the last quarter. Schroder Investment Management Group increased its position in Autolus Therapeutics by 133.7% during the 3rd quarter. Schroder Investment Management Group now owns 8,433,253 shares of the company’s stock valued at $13,409,000 after buying an additional 4,824,763 shares in the last quarter. Mak Capital One LLC boosted its stake in shares of Autolus Therapeutics by 15.3% during the 4th quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock worth $59,711,000 after acquiring an additional 3,987,727 shares during the last quarter. Finally, Cetera Investment Advisers grew its holdings in shares of Autolus Therapeutics by 37.3% in the fourth quarter. Cetera Investment Advisers now owns 1,099,750 shares of the company’s stock valued at $2,189,000 after purchasing an additional 298,500 shares in the last quarter. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Price Performance

Shares of NASDAQ AUTL traded down $0.05 during trading hours on Friday, reaching $2.31. 889,336 shares of the stock traded hands, compared to its average volume of 1,810,585. Autolus Therapeutics PLC Sponsored ADR has a 52-week low of $1.17 and a 52-week high of $2.58. The company’s 50-day simple moving average is $1.80 and its two-hundred day simple moving average is $1.63. The company has a quick ratio of 4.40, a current ratio of 4.89 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $614.83 million, a P/E ratio of -2.18 and a beta of 2.07.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.06. The firm had revenue of $45.69 million during the quarter, compared to analyst estimates of $38.56 million. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%. Equities research analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.75 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on AUTL. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, August 3rd. Wall Street Zen raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Finally, Weiss Ratings upgraded shares of Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.